HealthcareLarge capRs 48,487 crRs 40.3 cr traded a dayHealthcarePharmaceuticals
Close on 2026-08-21
1,911.20
+0.58%
52-week range100% of the way up
1,268.701,911.20
Market cap
48,487 cr
P/E (TTM)
35.3×
industry 44×
EPS (TTM)
54.20
Revenue YoY
+20.8%
Q1 FY27
Profit YoY
+82.2%
Net margin
15.2%
+5.1pt vs a year ago
Growth trend
+14.4pt
vs last quarter’s YoY
1 month
+7.9%
Below 52w high
0.0%
RSI (14)
67
Daily swing
4.0%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 40 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+10.21%
1 month
+7.90%
3 months
+21.12%
6 months
+25.51%
1 year
+39.75%
The read
written from the numbers on this page
The evidence leans constructive9 supporting, 1 against, 0 worth knowing
Supporting
trading 22% above its 200-day average
sitting at 100% of its 52-week range, with little overhead supply from trapped buyers
up 40% over twelve months
matches made a new 52-week high today, which has beaten the market by +1.03 points over 20 sessions across 9,118 past signals
3 of the scans it matches have a positive measured record
6 independent kinds of evidence agree today, which is uncommon
revenue grew 21% year on year in the quarter ending 2026-06-30
net margin has widened from 11.0% to 15.2% across four quarters
priced at 35× earnings against an industry median of 44× — 20% below its peers
Against
1 of the scans it matches has historically underperformed the market
Worth knowing
nothing the data supports either way
IPCALAB sits in Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 1,561, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
16 of 47 matched on 2026-08-21
IPCALAB matches 16 of the 47 scans today, across 6 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
IPCALAB trades at 35× trailing earnings, below its median of 44× over this window — 20% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 21% against the same quarter a year earlier
profit rose 82% year on year
net margin widened from 12.8% to 15.2%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
2,788
572
424
15.84
15.2%
Q4 FY26
2026-03-31 · consolidated
2,388
404
307
11.79
12.8%
Q3 FY26
2025-12-31 · consolidated
2,392
446
364
12.86
15.2%
Q2 FY26
2025-09-30 · consolidated
2,556
392
281
11.14
11.0%
Q1 FY26
2025-06-30 · consolidated
2,309
331
233
9.19
10.1%
Q4 FY25
2025-03-31 · consolidated
2,247
128
64
2.67
2.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+9.4%
Versus 200-day average+22.5%
Below 52-week high+0.0%
Above 52-week low+50.6%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)67.0
Higher closes in last 53 of 5
Six-month return+25.51%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.96%
Volume versus 20-day0.3x
Median daily turnoverRs 40.3 cr
Peers
Healthcare · 67 classified companies
IPCALAB trades at 35.3× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 20%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
2026-08-19
4
Closing in on a 52-week high, The market's strongest stocks, Made a new 52-week high today, Short averages stacked in order